Tumor glycolysis is typically assessed by in vivo PET using the cellular entrapment of 18F-FDG, after uptake of 18F-FDG by glucose transporters (GLUT-1, GLUT-3; often overexpressed in cancer) and subsequent phosphorylation by hexokinase II (256, 275). The gene discussed is SLC2A1; the disease is neoplasm.